Literature DB >> 26702800

Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment.

Juul M P A van den Reek1, Philippe A R R Pijls2, Marcia Tummers3, Piet C L M van Riel4, Wietske Kievit3, Frank Hoentjen2, Elke M G J de Jong5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26702800     DOI： 10.1016/j.jaad.2015.08.010

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  2 in total

1.  Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study.

Authors:  Alice Bitossi; Alessandra Bettiol; Elena Silvestri; Gerardo Di Scala; Daniela Bacherini; Giuseppe Lopalco; Vincenzo Venerito; Florenzo Iannone; Antonio Vitale; Gian Marco Tosi; Domenico Prisco; Stanislao Rizzo; Claudia Fabiani; Luca Cantarini; Gianni Virgili; Lorenzo Vannozzi; Giacomo Emmi
Journal:  Mediators Inflamm       Date:  2019-02-10       Impact factor: 4.711

2.  Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.

Authors:  Pei-Tzu Lin; Shu-Hui Wang; Ching-Chi Chi
Journal:  Sci Rep       Date:  2018-10-30       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.